Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Nobumichi Morishita"'
Autor:
Kenji Takazawa, Yoshiko Shimamura, Masami Fujita, Mika Ishii, Akihiro Ohnishi, Hideyuki Sanma, Masao Shimomura, Nobumichi Morishita, Jiro Hasegawa
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 25:551-562
E6010 is a novel modified human tissue plasminogen activator, in which cysteine 84 inthe epidermal growth factor domain of human tissue-type plasminogen activator (t-PA) isreplaced by serine.The safety, pharmacological activity and pharmacokinetics o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22a2073d8aad55ddba6ac0ae15b2c3ad
https://doi.org/10.3999/jscpt.25.551
https://doi.org/10.3999/jscpt.25.551
Autor:
Teruji Tanaka, Jiro Hasegawa, Yoshiro Tomono, Mitsuo Mihara, Katsuhiko Yamazaki, Akihiro Ohnishi, Hirotoshi Kamakura, Nobumichi Morishita
Publikováno v:
The Journal of Clinical Pharmacology. 33:1086-1091
E2020, a central-acting cholinesterase inhibitor, is now under clinical development as a potential therapeutic agent for senile dementia of Alzheimer type. In the current study, the authors compared the pharmacokinetics of this drug after single oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1012390e1348a576e8f796d1c5e0ea86
https://doi.org/10.1002/j.1552-4604.1993.tb01945.x
https://doi.org/10.1002/j.1552-4604.1993.tb01945.x
Autor:
Nobumichi Morishita, Yoshiro Tomono
Publikováno v:
Drug Investigation. 6:57-61
The dose-linearity of the pharmacokinetics of sustained-release bunazosin was studied in 12 healthy volunteers following single oral dose administration of a sustained-release formulation of bunazosin (Bunazosin Retard®; E1015) 3 to 18mg in an incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59a124c763ca1e3a51ef7bf23c522bc8
https://doi.org/10.1007/bf03258453
https://doi.org/10.1007/bf03258453
Autor:
Werner Weber, Nobumichi Morishita, Paul Branagan, Günther Pabst, A. C. Houston, Jiro Hasegawap, Yoshiro Tomono, Horst-Jürgen Heuer
Publikováno v:
Drug Investigation. 6:62-69
The results of 1 multiple dose and 2 single dose pharmacokinetic studies of sustained-release bunazosin (Bunazosin Retard®) 6mg in healthy elderly (n = 47) and healthy young (n = 12) volunteers are suggestive of an age-related difference in the drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::250f39751c452cd984a2bccdad620f5f
https://doi.org/10.1007/bf03258454
https://doi.org/10.1007/bf03258454
A Dose Dumping Study with a Sustained-Release Formulation of Bunazosin (E1015) in Healthy Volunteers
Autor:
Nobumichi Morishita, Norbert Bromet, Paul Branagan, Yoshiro Tomono, Maguy Bromet-Petit, Yves Mainguy
Publikováno v:
Drug Investigation. 6:1-4
The pharmacokinetics of a single oral dose of sustained-release bunazosin 6mg were compared under fasting and nonfasting conditions in 12 healthy volunteers. Following ingestion of a high fat (59g) meal, the extent of gastrointestinal absorption of b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::177e23f7e4db1fc3aaeca660d8025ce3
https://doi.org/10.1007/bf03259418
https://doi.org/10.1007/bf03259418
Publikováno v:
Drug Investigation. 6:5-9
An open-label randomised crossover study was undertaken to investigate the pharmacokinetics of intravenous bunazosin, and to determine the absolute bioavailabilities of the standard and sustained-release tablet formulations of the drug. 12 healthy vo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4133d4e5707d229ada0930aa41c3f933
https://doi.org/10.1007/bf03259419
https://doi.org/10.1007/bf03259419
Publikováno v:
Drug Investigation. 5:302-308
The results of short term (8-day) and longer term (28-day) pharmacokinetic studies in healthy male volunteers (n = 27) indicate that steady-state plasma bunazosin concentrations are achieved within 8 to 14 days on initiating multiple oral dose admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b1516e5ba5cdd94247a7c714d4cba60
https://doi.org/10.1007/bf03259235
https://doi.org/10.1007/bf03259235
Publikováno v:
Drug Investigation. 5:296-301
Investigation of the metabolism of 14C-bunazosin (2.0mg) in 3 healthy male volunteers indicated that the primary route of metabolism of this α1-adrenoceptor antagonist, as for other quinazoline derivatives, is via demethylation and hydroxylation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebc1215065c947a7399ac14be91628e
https://doi.org/10.1007/bf03259234
https://doi.org/10.1007/bf03259234
Autor:
Tamotsu Kanazawa, Yoshiaki Yamano, Youji Yamagishi, Hiromu Nakai, Tadasu Ogawa, Nobumichi Morishita, Kouji Yamada
Publikováno v:
Journal of Chromatography B: Biomedical Sciences and Applications. 528:199-207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8550d560c2315a185dfe64e514a8d7
https://doi.org/10.1016/s0378-4347(00)82376-2
https://doi.org/10.1016/s0378-4347(00)82376-2
Autor:
Hirotsugu Atarasi, Nobumichi Morishita, Hirokazu Hayakawa, Hiroyuki Sasaki, Yoshiro Tomono, Emiko Oosuga
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 21:623-634
A Phase I study of E-1020, a new positive inotropic agent, was performed on normal healthy volunteers to define its pharmacological characteristics, safety, and tolerance. The study evaluated both single (0.5, 1.0, 2.5, 5.0, 10.0, and 20.0 mg, n=4 fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ebd77d20f61cd8782937e7ba6c2a3c0
https://doi.org/10.3999/jscpt.21.623
https://doi.org/10.3999/jscpt.21.623